30 closest matches · ranked by relevance
Gonococcal Infection
Primary: The Competitive Index of the Mutant Compared to Wild Type Proportion of Organisms With the Predicted Competitive Advantage Recovered From Urine and/or Urethral Swab…
Gonococcal Infection
Primary: The Proportion of Participants That Become Infected With Individual N. Gonorrhoeae Strains in Non-competitive Infections — 0.80; 1.00 proportion of participants — p=1.000
Gonorrhoea
Primary: Microbiological Efficacy of Gentamicin and Azithromycin for the Treatment of Uncomplicated Gonococcal Infection — 100 percentage of participants — p=<0.05
Neisseria Gonorrhoeae
Primary: Macrolide Resistance Determinants — 110.3; 167.53 normalized determinants/million reads — p=0.1026
Gonorrhea of Pharynx · Gonorrhea
Primary: Treatment Efficacy of Pharyngeal Gonorrhea as Defined as the Proportion of Study Participants With Positive Pharyngeal Gonorrhea Culture at of Enrollment Whose Test of…
Urethritis
Primary: mITT Analysis of Eradication of M. Genitalium at First Follow-up Study Visit — 15; 8 participants
Urethritis
Primary: Safety and Tolerability of Doxycycline/Tinidazole and Azithromycin/Tinidazole: Number of Participants Reporting Nausea — 3; 4; 0; 4 Participants
Neisseria Gonorrhoeae Infection · Chlamydia Trachomatis Infection
Primary: Incidence Rate of Ng Plus Ct Detected at Any Site Whilst Individuals Are Screened vs. Not Screened — 0.155; 0.205 Ng or CT cases per study visit
Gonorrhea
Primary: Number of Participants With Culture-confirmed Bacterial Eradication of Urogenital Neisseria Gonorrhoeae at the Test-of-Cure Visit — 29; 37 Participants
Urethritis · Cervicitis · Sexually Transmitted Infections
Primary: Mean Antibiotic Days of Therapy (DOT) Administered Per Patient With Symptomatic Urethritis or Cervicitis — 7; 1 Antibiotic days of therapy (DOT) — p=0.053
Gonococcal Infection
Primary: The Percentage of Subjects Infected With Gyrase A (gyrA) Serine 91 Genotype of Neisseria Gonorrhoeae (N. Gonorrhoeae) With Microbiological Cure — 100 percentage of…
Gonorrhoea
Primary: Rectal Mucosal IgG Concentrations (Geometric Mean Titers [GMT]) Against N. Gonorrhoeae Outer Membrane Vesicle (OMV) Antigen Ng1291 — 0.07; 0.072; 0.089; 0.097 titer
Gonorrhea
Primary: Number of Participants With Culture-Confirmed Bacterial Eradication of Neisseria Gonorrhoeae (NG) From the Urogenital Site at the Test-Of-Cure (TOC) Visit (Day 4 to 8)…
Neisseria Gonorrhoeae Infection
Primary: Change in Anti-N. Gonorrhoeae Outer-membrane Vesicle Specific Immunoglobulin G (IgG) Concentrations After Immunization — 61.57; 206.2 titers
Gonorrhoea
Primary: Number of Participants With Microbiological Cure at Urethral or Cervical Sites in Each Study Arm — 55; 54; 28 Participants
Chlamydial Infection
Primary: Assess Microbiological Failure of Recommended Azithromycin and Doxycycline Regimens in Uncomplicated Chlamydia Trachomatis Infection in a Setting Where Repeat Exposure…
Chlamydial Infection
Primary: Proportion of Participants Experiencing Treatment Failure After Treatment With Azithromycin for Uncomplicated Chlamydia Trachomatis (CT) in Males With and Without…
Anal Chlamydia Infection
Primary: The Proportion of Subjects With Microbiologic Cure (Negative Rectal CT NAAT Result) at Day 29 — 0.74; 1.00 proportion of participants — p=<0.001
Gonorrhea · Chlamydia · Meningococcal Vaccines
Primary: Number of Participants With Gonococcal Infection After at Least 1 Dose of Trumenba to Determine Vaccine Effectiveness (VE) — 316; 2327 Participants
Recurrent Bacterial Vaginosis
Primary: Number of Female Partners Whose Male Partners Received Metronidazole Versus Females Whose Male Partners Did Not Receive Metrodiazole With Recurrence of BV in the Female…
Gonorrhea
Primary: Microbiological Cure Rate for Zoliflodacin Compared to a Combination of a Single Dose of Ceftriaxone and Azithromycin. — 90.9; 96.2 percentage of participants
Gonorrhea Male · Chlamydia;M
Primary: Number of Participants Who Received the Dual Gonorrhea/Chlamydia Testing — 57; 46; 18 Participants
Sexually Transmitted Diseases · Gonorrhea · Chlamydia
Primary: Percentage of Study Successes in the EVO100 and Placebo Treatment Groups — 684; 696 Participants
Human Immunodeficiency Virus · Virus Shedding
Primary: Semen Clearance (CL) of Tenofovir — 33.88; 51.21; 5.65 L/hr
Contraception
Primary: The Number of Men Who Have Suppression of Sperm Production ≤1Million/mL Million/mL When Using a Daily Regimen of Nestorone® Gel (0, 8 or 12 mg) and Testosterone Gel…
Chlamydia Trachomatis Infection · Neonatal Infection · Preterm Birth
Primary: Number of Women Diagnosed With C. Trachomatis and N. Gonorrhoeae Infection at Post-delivery — 2; 23 Participants
Gonorrhea · Chlamydia
Primary: Number of Participants Testing for Gonorrhea and Chlamydia — 390; 361; 12 Participants — p=<0.001
Urinary Tract Infections
Primary: Resolution of UTI Symptoms 14 Days After Completing Active Antimicrobial Therapy — 111; 122 Participants
Sexually Transmitted Diseases · Gonorrhea · Chlamydia
Primary: Number of Participants That Schedule a Pre-test Session — 74 Participants
Tuberculosis, Pulmonary · Tuberculosis, Multidrug-Resistant · Tuberculosis, MDR
Primary: Change Form Baseline Total Sperm Count — 20 10^6 sperm cells/ejaculate